All you need to know about hereditary hemorrhagic telangiectasia.

The development of hereditary haemorrhagic telangiectasia is due to genetic mutations on autosomal genes, that is, those carried by non-sex chromosomes. This pathology thus affects both men and women. The transmission is said to be autosomal dominant because it is sufficient for the anomaly to affect a single copy of the gene for the disease to develop. Several studies have looked into the etiology of hereditary haemorrhagic telangiectasia and have determined that over 80% of affected patients present mutations in one of the following genes:

• Endoglin Gene (ENG) : This gene encodes for a homodimeric transmembrane protein, which is a major glycoprotein of the vascular endothelium. This protein is a component of the transforming growth factor beta (TGF-β) receptor complex and it binds to TGF-β1 and TGF-β3 with high affinity. It is primarily expressed in endothelial cells, activated monocytes, and tissue macrophages.

• Activin A receptor-like type 1 gene (ACVRL1) : This gene codes for activin receptor-like kinase (ALK1), a cell surface receptor for ligands of the TGF-beta family. It is predominantly expressed in endothelial cells, but also in lung and placental cells.

• Gene SMADH4 (MADH4) : this gene codes for the SMAD4 protein, playing a major role in the TGF beta signalling pathway.

Hereditary haemorrhagic telangiectasia is caused by a disruption in the TGF signalling pathway. This pathway plays a significant role in the regulation of many cellular processes such as proliferation, differentiation, adhesion, and migration. Moreover, the genes affected by mutations are necessary for the development and maintenance of arteriovenous identity, as well as the recruitment and differentiation of smooth muscle cells during the development of the vascular system.

The management of hereditary haemorrhagic telangiectasia depends on the organ affected. The goal is to prevent and stop bleeding. Treatment may include applying pressure, using a topical medication with a vasoconstrictive effect, or a laser beam to destroy the affected blood vessels in the nose or digestive tract. In the case of severe bleeding, surgery may be considered. An oral iron supplement is also typically prescribed.

Certain medications, such as bevacizumab, pazopanib, or pomalidomide, may also be prescribed in order to reduce the number and density of abnormal blood vessels. Finally, to minimise bleeding and inhibit the breakdown of blood clots, patients may require regular blood transfusions. These transfers are carried out from a healthy individual to a person suffering from hereditary haemorrhagic telangiectasia and must take into account the compatibility of blood groups.